[go: up one dir, main page]

DK3102209T3 - Anvendelse af flap-hæmmere til at reducere neuroinflammationsmedieret læsion i centralnervesystemet - Google Patents

Anvendelse af flap-hæmmere til at reducere neuroinflammationsmedieret læsion i centralnervesystemet Download PDF

Info

Publication number
DK3102209T3
DK3102209T3 DK15705756.3T DK15705756T DK3102209T3 DK 3102209 T3 DK3102209 T3 DK 3102209T3 DK 15705756 T DK15705756 T DK 15705756T DK 3102209 T3 DK3102209 T3 DK 3102209T3
Authority
DK
Denmark
Prior art keywords
inflammation
nervous system
central nervous
flap inhibitors
mediated laser
Prior art date
Application number
DK15705756.3T
Other languages
English (en)
Inventor
Kim A Heidenreich
Robert C Murphy
Original Assignee
Bioscience Pharma Partners Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioscience Pharma Partners Llc filed Critical Bioscience Pharma Partners Llc
Application granted granted Critical
Publication of DK3102209T3 publication Critical patent/DK3102209T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15705756.3T 2014-02-04 2015-02-04 Anvendelse af flap-hæmmere til at reducere neuroinflammationsmedieret læsion i centralnervesystemet DK3102209T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461935763P 2014-02-04 2014-02-04
PCT/US2015/014443 WO2015120038A1 (en) 2014-02-04 2015-02-04 Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system

Publications (1)

Publication Number Publication Date
DK3102209T3 true DK3102209T3 (da) 2021-07-12

Family

ID=53753907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15705756.3T DK3102209T3 (da) 2014-02-04 2015-02-04 Anvendelse af flap-hæmmere til at reducere neuroinflammationsmedieret læsion i centralnervesystemet

Country Status (8)

Country Link
US (1) US10080748B2 (da)
EP (2) EP3906925A1 (da)
CN (1) CN106456624B (da)
AU (1) AU2015214317B2 (da)
CA (1) CA2938879C (da)
DK (1) DK3102209T3 (da)
ES (1) ES2878405T3 (da)
WO (1) WO2015120038A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9949934B1 (en) * 2016-10-20 2018-04-24 Intelgenx Corp. Device and method of treating conditions associated with neuroinflammation
EP3618824A4 (en) * 2017-05-02 2021-06-23 Neuronasal, LLC Use of n-acetylcysteine to treat central nervous system disorders
CA3164091A1 (en) * 2019-12-26 2021-07-15 Centro De Investigacion Y Desarrollo De Medicamentos Cidem Use of a benzodiazepine derivative and method of treatment of traumatic brain injury

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081138A (en) 1986-12-17 1992-01-14 Merck Frosst Canada, Inc. 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith
DE3814504A1 (de) 1988-04-29 1989-11-09 Bayer Ag (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE3900261A1 (de) 1988-05-31 1989-12-07 Bayer Ag Substituierte 4-(chinolin-2-yl-methoxy) phenyl-essigsaeure-derivate
US5204344A (en) 1989-08-22 1993-04-20 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
US5272145A (en) 1989-08-22 1993-12-21 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
DE3927931A1 (de) 1989-08-24 1991-02-28 Bayer Ag Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate
US5229516A (en) 1989-10-27 1993-07-20 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
US5304563A (en) 1991-02-22 1994-04-19 Bayer Aktiengesellschaft 2-substituted quinolines, and their use in medicaments
DE4139751A1 (de) 1991-12-03 1993-06-09 Bayer Ag, 5090 Leverkusen, De Thiazolyl substituierte chinolylmethoxyphenylessigsaeurederivate
DE4128681A1 (de) 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
CA2129429A1 (en) 1992-02-13 1993-08-14 Richard Frenette (azaaromaticalkoxy) indoles as inhibitors of leukotriene biosynthesis
US5334719A (en) 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
DE4226519A1 (de) 1992-08-11 1994-02-17 Bayer Ag 3-Substituierte Chinolylmethoxy-phenylessigsäurederivate
US5288743A (en) 1992-11-20 1994-02-22 Abbott Laboratories Indole carboxylate derivatives which inhibit leukotriene biosynthesis
IL109254A (en) 1993-04-29 1999-03-12 Zeneca Ltd History of the tetrahydropyran and tetrahydropuran site preparation and pharmaceutical preparations containing them
US5399699A (en) 1994-01-24 1995-03-21 Abbott Laboratories Indole iminooxy derivatives which inhibit leukotriene biosynthesis
US5512581A (en) 1994-07-18 1996-04-30 Abbott Laboratories Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
US5714488A (en) 1995-10-03 1998-02-03 Abbott Laboratories Bis-heteroarylylmethoxyphenyl ketone derivatives as inhibitors of leukotriene biosynthesis
US5795900A (en) 1995-10-03 1998-08-18 Abbott Laboratories Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5668146A (en) 1995-10-03 1997-09-16 Abbott Laboratories Symmetrical bis-heteroarylmethoxyphenyliminoxyalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5691351A (en) 1996-02-06 1997-11-25 Abbott Laboratories Bis-(Heteroarylmethoxyphenyl)cycloalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5668150A (en) 1996-07-26 1997-09-16 Abbott Laboratories Non-symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
US5783586A (en) 1996-10-01 1998-07-21 Abbott Laboratories Heteroarylmethoxyphenylthioalkyl carboxylates as inhibitors of leukotriene biosynthesis
ATE342918T1 (de) 1998-04-15 2006-11-15 Serono Genetics Inst Sa Genomische sequenz des 5-lipoxygenase- aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
AU2002222910A1 (en) 2000-07-13 2002-01-30 Bristol-Myers Squibb Company Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
JP2008526894A (ja) 2005-01-10 2008-07-24 レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア Cox阻害剤および5−lox阻害剤の活性を助けるための可溶性エポキシドヒドロラーゼの阻害剤の使用
CA2594777A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflamation
AU2006279325B2 (en) * 2005-08-18 2013-06-27 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
EP1926708B1 (en) 2005-09-21 2014-06-18 Decode Genetics EHF Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US20070244128A1 (en) 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
JP2010511632A (ja) 2006-11-30 2010-04-15 アミラ ファーマシューティカルス,インコーポレーテッド 5−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法
WO2009002746A1 (en) 2007-06-22 2008-12-31 Decode Genetics Ehf. Dosing schedules of leukotriene synthesis inhibitors for human therapy
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US20120027842A1 (en) 2008-12-23 2012-02-02 Amira Pharmaceuticals, Inc. Topical formulations of flap inhibitors for administration to an eye
EP2381945A4 (en) 2008-12-23 2012-06-13 Panmira Pharmaceuticals Llc TOPICAL FORMULAS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES
US20120232031A1 (en) 2009-10-19 2012-09-13 Panmira Pharmaceuticals, Llc Injectable formulations for intra-articular or peri-articular administration
AU2012318391A1 (en) 2011-10-07 2014-05-15 Florida State University Research Foundation Prophylactic and post-acute use of progesterone to better outcomes associated with concussion
US20130310421A1 (en) * 2012-05-18 2013-11-21 Temple University - Of The Commonwealth System Of Higher Education Treatment of amyloid beta amyloidosis
CN103110945A (zh) * 2013-03-04 2013-05-22 中国药科大学 一种单核细胞抗体在治疗炎症相关抑郁症中的应用

Also Published As

Publication number Publication date
CN106456624B (zh) 2020-05-22
ES2878405T3 (es) 2021-11-18
AU2015214317A1 (en) 2016-09-01
US20150216854A1 (en) 2015-08-06
EP3102209A1 (en) 2016-12-14
CN106456624A (zh) 2017-02-22
US10080748B2 (en) 2018-09-25
CA2938879A1 (en) 2015-08-13
AU2015214317B2 (en) 2020-01-16
EP3906925A1 (en) 2021-11-10
CA2938879C (en) 2023-05-09
WO2015120038A1 (en) 2015-08-13
EP3102209B1 (en) 2021-04-07

Similar Documents

Publication Publication Date Title
HK1243333A1 (zh) 用於修飾的t細胞的方法和組合物
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
HK1221403A1 (zh) 用於調節載脂蛋白 表達的組合物和方法
DK3116533T3 (da) Deletion af dystrophingenexon under anvendelse af genmanipulerede nukleaser
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
FR3018941B1 (fr) Pilotage de vehicules en convoi
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3145420T3 (da) Intraoperativ fremgangsmåde til tracking
DK3193931T3 (da) Neutralisering af hæmmende veje i lymfocytter
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3182962T3 (da) Compositions and uses of amidine derivatives
DK3204038T3 (da) Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus
DK3341379T3 (da) EZH2-hæmmere
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3204352T3 (da) Hæmmere af lysin-gingipain
MA41266A (fr) Cataplasme
DK3418273T3 (da) Derivater af flavagliner